Investor Materials and Voting

Annual Report

View an enhanced version of
our Annual Report.

Proxy Statement

View an enhanced version of
our Proxy Statement.

Request Materials

Request paper copies online now, by email or by phone by dialing 866-648-8133.

Vote Now

You may vote online or by phone. To vote by phone dial 866-892-1437.

Meeting Details


May 24, 2023

Virtual Meeting

Note: You must register to be eligible to participate in the meeting.


9:00 a.m. Eastern Time

About Us

Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE™ platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue. Dyne has a broad pipeline for serious muscle diseases, including clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and a preclinical program for facioscapulohumeral muscular dystrophy (FSHD).